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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motoneurons which
progresses differentially in males and females for unknown reason. Here we measured
gender differences in pre- and post-synaptic parameters of the neuromuscular transmis-
sion in a mutant G93A-SOD1 mouse model of ALS. Using intracellular microelectrode
technique we recorded miniature and evoked end-plate potentials (MEPPs and EPPs) in
the diaphragm muscle of G93A-SOD1 mice at early symptomatic stage.While no evident
alterations in the amplitude of MEPPs was observed in male or female G93A-SOD1 mice,
G93A-SOD1 mice displayed dramatically reduced probability of spontaneous acetylcholine
release. In contrast, the EPPs evoked by single nerve stimulation had unchanged amplitude
and quantal content. In males, but not females, this was accompanied by reduced readily
releasable transmitter pool.Transmitter release in both sexeswas sensitive to the inhibitory
action of reactive oxygen species (ROS), but the production of ROS was increased in the
spinal cords of male but not female G93A-SOD1 mice. Treatment with granulocyte colony
stimulating factor (GCSF), which we previously found to be beneﬁcial in males, attenuated
the increased ROS production indicating involvement of the antioxidant mechanisms and
improved ALS-induced synaptic dysfunctions only in males being ineffective in females.
Consistent with our ﬁndings at synaptic level, GCSF did not change the survival rate or
motor performance of female ALS mice. In summary, neuromuscular transmission in ALS
mice is impaired at early symptomatic stage when a dramatic presynaptic decline of spon-
taneous release occurs. Beneﬁcial effects of GCSF treatment on survival in males may
be explained by GCSF-improved presynaptic functions in male G93A-SOD1 mice. Develop-
ment of efﬁcient treatment strategies for ALS may need to be directed in a gender-speciﬁc
manner.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neu-
rodegenerative disease leading to motoneuron death (Boillée et al.,
2006; Rothstein, 2009). While 90% of the cases are sporadic, 20%
of the remaining familial cases are caused by dominant muta-
tions in the Cu/Zn superoxide dismutase (SOD1) gene (Valdmanis
and Rouleau, 2008). Even though sporadic and familial forms
of the disease display similar clinical features, a direct causative
pathway to neuronal dysfunction and death has not yet been
established. The central neuropathology of the disease, motoneu-
ron degeneration, appears to be associated with accumulation of
mutant SOD1 (Boillée et al., 2006). Such progressive neurode-
generation is observed in transgenic mice overexpressing mutant
forms of human SOD1 (Shibata, 2001). Since the main function
Abbreviations: Ach, acetylcholine; ALS, amyotrophic lateral sclerosis; EPPs, evoked
end-plate potentials; GCSF, granulocyte colony stimulating factor; MEPPs, minia-
ture end-plate potentials; ROS, reactive oxygen species; RRP, readily releasable pool;
SOD1, Cu/Zn superoxide dismutase.
of the motoneuron is the transmission of motor commands to
the muscle, it is important to characterize the electrophysiological
parameters of neurotransmission in ALS. While numerous mor-
phological studies indicate early distal axon degeneration (Fischer
et al., 2004; David et al., 2007), only one electrophysiological study
reported decreased amplitudes of miniature end-plate potentials
(MEPPs) but unchanged average MEPP frequency along with
reduced end-plate potentials (EPPs) quantal content in muscle
biopsies taken from patients with clinical features of ALS (Maselli
et al., 1993).
Epidemiological studies show that both the incidence and
prevalence of ALS are greater in men than in women (McCombe
and Henderson, 2010). Sex differences have also been reported
in genetic mouse models overexpressing mutant SOD1. Thus, in
female G93A-SOD1 mice, the onset is delayed compared to male
G93A-SOD1 littermates. It has been shown that gender inﬂuences
disease onset but not the progressive loss of motor units (Hege-
dus et al., 2009; Alves et al., 2011). However, the mechanisms
underlying the role of gender in ALS and whether suggested
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treatments should take into account sexual dimorphism remain
only partially understood.
Oxidative stress has often been implicated as a main rea-
son for motoneuron death in ALS patients (Barber and Shaw,
2010; Cova et al., 2010). Morphological studies performed in
G93A-SOD1 mice suggest that synapses are highly sensitive to
ischemia/reperfusion injury (David et al., 2007), probably via free
radicals. Although antioxidants have beneﬁcial effects in some
ALS animal models, no conﬁrmation in human trials has been
obtained (Barber and Shaw, 2010). This suggests that antioxidant
therapy should probably be supplemented with additional neuro-
protective treatments. One promising and clinically safe agent is
granulocyte colony stimulating factor (GCSF), which prolonged
survival in an animal model of ALS (Pitzer et al., 2008; Pollari
et al., 2011). However, the cellular targets and the mechanisms of
its beneﬁcial effect remain largely unknown. In the present study,
we tested the functional state of the neuromuscular junctions in
G93A-SOD1 mice at early symptomatic stage of ALS and in ani-
mals treated with GCSF and investigated whether there are gender
differences in neuromuscular junction function and in response
to GCSF treatment.
MATERIALS AND METHODS
ANIMALS
Transgenic G93A-SOD1 (B6.Cg-Tg-(SOD1-G93A)1Gur/J) mice
carrying a high copy number of human mutant G93A-SOD1 were
obtained from Jackson laboratory and maintained on C57BL con-
genic background. Themotor deﬁcits appear at the age of 19 weeks
in both the male and female mice reaching the end stage at the age
of 24–26 weeks. The onset of the disease was determined with a
wire-hang test as an inability to complete the 3 min observation
period. The clinical end stage was determined as the inability of
a mouse to right itself in a period of 30 s which was deﬁned as a
criterion for mouse sacriﬁce. The mice were used for electrophys-
iological studies at the early symptomatic stage at 20 weeks of age.
For FOX1 assay spinal cords were collected at symptomatic stage
at the age of 20–22 weeks. Animal experiments were conducted
according to the national regulations of the usage and welfare
of laboratory animals and approved by the Animal Experiment
Committee in State Provincial Ofﬁce of Southern Finland.
TREATMENT
In this study setup G93A-SOD1 mice were treated with pegﬁlgras-
tim, GCSF with sustained action (Neulasta, Amgen, Breda, The
Netherlands) at the dosage of 300 μg/kg given subcutaneously
once per week. Pegﬁlgrastim was diluted into 0.15 M sodium
acetate right before use while sodium acetate injections were
used as a vehicle control. The treatment was started at the age
of 12 weeks at the presymptomatic stage and continued until the
mouse was sacriﬁced. The littermates were randomly divided into
treatment groups.
ELECTROPHYSIOLOGICAL RECORDINGS
Electrical recordings were made from diaphragm muscle kept at
room (∼21˚C) temperature. In total 45 mice of both sexes (from
4 to 11 animals in a group) were used for electrophysiological
recordings. Mice were decapitated under carbon dioxide anesthe-
sia (100% CO2 for several seconds until the loss of reﬂexes) and
diaphragms were immediately dissected. Preparations were placed
in a small chamber continuously superfused with gassed (95%
O2/5% CO2) Krebs solution containing (in mM): 120 NaCl, 5 KCl,
2 CaCl2, 1 MgCl2, 11 glucose, 1 NaHPO4, 24 NaHCO3, pH was
adjusted to 7.4. EPPs and MEPPs were recorded using a low-noise
custom-made ampliﬁer and standard microelectrodes technique
(8–15 MΩ electrode resistance when ﬁlled with 3 M KCl) typi-
cally during 2 min (10–20 s in sucrose test). Each diaphragm was
dissected into two to four muscle strips and 4–12 synapses were
sampled in each strip. For recording evoked potentials the left
phrenic nerves (14–16 mm length) were dissected together with
the diaphragm. To evaluate the readily releasable pool (RRP) of
transmitter in nerve terminals we used hypertonic sucrose solu-
tion (Kashani et al., 2001; Moulder and Mennerick, 2005; Virmani
et al., 2005; Vanden Berghe and Klingauf, 2007). In the sucrose
test recordings were made in the interval of 5–10 min in the sus-
tain phase of stimulated release induced by bath application of
500 mM sucrose (Sara et al., 2002). In experiments with record-
ing of spontaneous MEPPs and sucrose test 1 μM tetrodotoxin
(TTX, Ascent scientiﬁc, UK) was present during recordings. To
block muscle contractions and preserve the physiological level of
transmitter release in the experiments with motor nerve stimula-
tion we used transverse cutting of muscle ﬁbers (Giniatullin et al.,
1993). EPPs were induced by the suprathreshold stimulation of
the phrenic nerve via a suction electrode connected to an isolated
pulse stimulator Model 2100 (A-M Systems,USA). EPPs (recorded
at the membrane potential∼39–47 mV) and MEPPs (recorded at
the membrane potential ∼69–72 mV) were digitized at 50 kHz
and acquired to the PC using the data acquisition board NI
PCI6221 (National Instruments, Austin, TX, USA) and visualized
with the WinEDR V3.0.4 software (Strathclyde University, UK).
Amplitudes of EPPs and MEPPs, interevent intervals of MEPPs
were analyzed off-line with the WinEDR V3.0.4 and ClampFit
V10.2.0.14 (Molecular Devices, Sunnyvale, CA, USA) software.
Subsequent statistical analysis was made using the Origin graphic
software (v.8.0, OriginLab Corp, Northampton, MA, USA).
FOX1 ASSAY
Concentration of hydroperoxides in the spinal cord samples were
measured with the FOX1 assay of ferrous oxidation in xylenol
orange (Wolff, 1994; Giniatullin et al., 2005; Morgan et al., 2008).
In short, this method is based on oxidation of ferrous ions in an
acidic medium containing the dye xylenol orange, which binds
the resulting ferric ions to produce a complex with absorbance
maximal at 560 nm. The FOX reagent was prepared as described
by Wolff (1994) with slight modiﬁcation: 1 part 25 mM hep-
tahydrate ammonium ferrous sulfate, 2 parts H2O, and 2 parts
10 mM xylenol orange. After addition of cold (-20˚C) acetone as
a ﬁxative the spinal cord samples were homogenized, sonicated,
and centrifuged for 8 min at 12000 g. The supernatant for the
assay was mixed with 50 μl of the FOX reagent. After completion
of the reaction the tissue extracts were centrifuged for 3 min at
10000 g, and the supernatant was assayed spectrophotometrically
(absorbance at 560 nm). The peroxide content of samples was
determined with reference to a calibration curve obtained with
known concentrations of H2O2 and expressed as micromoles of
peroxide per milligram of tissue.
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STATISTICAL ANALYSIS
Although we collected and averaged data from each synapse, as the
basic statistical approach we compared averaged data from each
mouse. Thus, all data are presented as the mean± SEM with indi-
cation of number of animals used. Signiﬁcance was assessed using
Student’s t -test. Kaplan–Meier survival statistics with a log rank
sum test was used for testing differences in survival. A P value of
less than 0.05 was accepted as indicative of a statistically signiﬁcant
difference.
RESULTS
EFFECT OF GCSF ON SURVIVAL OF G93A-SOD1 MICE: THE GENDER
DIFFERENCE
Wehave shown, in the parallel study, that pegﬁlgrastim,GCSFwith
a sustained action, prolonged the survival of G93A-SOD1 male
mice from 173± 7 to 185± 7 days (Pollari et al., 2011). When in
the current project, we treated the female G93A-SOD1 mice with
pegﬁlgrastim in the similar manner, surprisingly we did not detect
any effect of GCSF on survival (P = 0.30, Figure 1). In addition,
GCSF did not improve the motor performance in female G93A-
SOD1 mice as assessed with wire-hang test (data not shown) as
we previously detected in male G93A-SOD1 mice (Pollari et al.,
2011). The life span was longer (by 15.0 ± 3.3 days, P = 0.001) in
female G93A-SOD1 mice than in male G93A-SOD1 mice. The
similar results were previously reported by Alves et al. (2011). This
ﬁnding indicates that even though GCSF treatment signiﬁcantly
extends the lifespan of male ALS mice, it may be almost ineffective
in female ALS mice. Therefore, in the current study we aimed to
elucidate gender-dependent synaptic mechanisms of ALS devel-
opment and cellular mechanisms of differential sensitivity to the
therapeutic effectiveness of GCSF.
FIGURE 1 |The time course of survival for female G93A-SOD1 mice
with or without GCSF treatment (Kaplan–Meier survival graph).The
female G93A-SOD1 mice were treated with GCSF starting at the age of
12weeks. In contrary to the previous results we obtained from male
G93A-SOD1 mice (Pollari et al., 2011), GCSF did not prolong the survival of
female G93A-SOD1 mice (n =8–10).
LOW PROBABILITY OF TRANSMITTER RELEASE IN G93A-SOD1 MICE
In order to link disease related behavior, motor function changes,
and sex-dependent effectiveness of the treatment with mech-
anisms of neuromuscular transmission, we recorded synaptic
potentials in G93A-SOD1 mice at the symptomatic disease stage
of 20 weeks when the pathological changes in behavior such as
abnormal reﬂexes and decreased motor performance were evi-
dent. Independent from the sex or treatment all the mice reached
the disease onset at age of 19 weeks as determined by the wire-
hang test (data not shown). In the isolated diaphragm muscle
taken from 20 week old G93A-SOD1 male mice only a trend
toward the reduced amplitude of MEPP was observed. Thus,
in males, MEPPs amplitude was 0.41± 0.06 mV (n = 8 mice) in
the WT, 0.26± 0.02 mV in untreated G93A-SOD1 mice (n = 6
mice, P = 0.054 versus WT,) and 0.30± 0.04 mV (n = 5 mice,
P = 0.42 versus G93A-SOD1) in the G93A-SOD1 mice treated
with GCSF (Figures 2A–D). These data indicated that the func-
tional state of the postsynaptic membrane in muscle ﬁbers was
not signiﬁcantly affected, although P value was approaching the
P < 0.05 limit, thus not excluding the possibility that with higher
number of animals the difference between G93A-SOD1 and WT
mice in the amplitude of postsynaptic responses could become
signiﬁcant.
In sharp contrast, the rate of spontaneous quantal acetyl-
choline (ACh) release from motor nerve endings (evaluated as
the interevent intervals between single MEPPs, the longer interval
indicated reduced frequency) was dramatically reduced in male
G93A-SOD1 mice. Moreover, there was a huge variability in the
rate of transmitter release in G93A-SOD1 mice most visible if we
present data for each synapse (Figure 3A). Such large dispersion
FIGURE 2 | Spontaneous transmitter release at the neuromuscular
junctions ofWT, G93A-SOD1, and GCSF-treated G93A-SOD1 mice.
(A–C) Examples of miniature end-plate potentials (MEPPs) inWT,
G93A-SOD1, and GCSF-treated G93A-SOD1 mice, respectively (right,
averaged MEPPs are shown in expanded scale). Note largely reduced
frequency of MEPPs in G93A-SOD1 mice and improvement of this
parameter in GCSF-treated animals. (D,E). Histograms showing MEPPs
amplitude inWT, G93A-SOD1, and GCSF-treated G93A-SOD1 mice in males
(D) and females (E) 80–140 MEPPs were averaged in every group.
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of MEPP frequency in G93A-SOD1 mice suggested that synapses
were in different stages of disease progression. Comparing sponta-
neous quantal events,we found in symptomatic male G93A-SOD1
mice the interevent intervals as high as 9.45 ± 1.60 s (n = 6 mice)
versus 1.59± 0.07 s in WT mice (n = 8 mice, P = 0.0001). GCSF
reduced this parameter to 3.48± 0.21 s (n = 5 mice, P = 0.009,
Figure 3A).
In the WT females the amplitude of MEPPs was larger than
in males (0.56± 0.04 mV, n = 10 mice, P < 0.0001) and was
unchanged in G93A-SOD1 female mice without (0.52± 0.04 mV,
n = 11 mice, P = 0.43) or with GCSF treatment (0.50± 0.05 mV,
n = 5 mice, P = 0.77, Figure 2E).
In females, like in males, spontaneous release was strongly com-
promised inG93A-SOD1mice.We found that themean interevent
interval was strongly increased from 1.82 ± 0.14 (n = 10 mice)
to 9.63± 1.70 s (n = 11 mice, P = 0.0003 versus WT) in G93A-
SOD1 females. However, we did not ﬁnd signiﬁcant improvement
with GCSF treatment (5.53± 1.08 s, n = 5 mice, P = 0.14 versus
G93A-SOD1 mice, Figure 3B).
To sum up, G93A-SOD1 mice of both sexes had signiﬁcantly
reduced probability of spontaneous transmitter release and this
parameter was signiﬁcantly restored in males but not in females
by GCSF treatment.
READILY RELEASABLE POOL OF ACH AND Ca2+-DEPENDENT EVOKED
RELEASE
In order to ﬁnd reasons for reduced probability of spontaneous
ACh release in ALS mice we measured the level of RRP of synaptic
vesicles. The size of RRP is usually estimated by hypertonic treat-
ments which trigger the intensive exocytosis from this transmitter
pool (Kashani et al., 2001; Moulder and Mennerick, 2005;Virmani
et al., 2005; Vanden Berghe and Klingauf, 2007). To this end, we
appliedhypertonic 500 mMsucrose solutionwhich induced a large
increase in the rate of quantal release (by shortening interevent
intervals). Thus, in theWTmales, interevent intervals after sucrose
applicationwere shortened to 0.076± 0.011 s (n = 6mice)while in
the G93A-SOD1 male mice they were shortened to 0.423± 0.170 s
(n = 6 mice,P = 0.01 versus WT) indicating diminished RRP. The
FIGURE 3 | Interevent intervals of spontaneous MEPPs at the
neuromuscular junctions ofWT, G93A-SOD1, and GCSF-treated
G93A-SOD1 mice. (A,B). Histograms showing mean interevent intervals of
MEPPs (left axis) in theWT, G93A-SOD1, and GCSF-treated G93A-SOD1
male (A) and female (B) mice. Each dash line indicates individual synapse
(right axis). Note huge variability of release probabilities between individual
synapses. **=P <0.01, ***=P <0.001.
treatment with GCSF in males signiﬁcantly restored the amount of
synaptic vesicles in the RRP (0.091± 0.015 s, n = 5 mice, P = 0.02
versus G93A-SOD1, Figures 4A–D).
In females, interevent intervals in the WT mice after sucrose
application were shortened to 0.055± 0.006 s (n = 5 mice)
while in the G93A-SOD1 female mice they were shortened
to 0.112± 0.034 s (n = 6 mice, P = 0.17 versus WT). GCSF
did not change signiﬁcantly sucrose-induced transmitter release
(0.080± 0.021 s, n = 5 mice, P = 0.47 versus G93A-SOD1 mice,
Figure 4E). Thus, unlike in males, RRP was not signiﬁcantly
compromised in female G93A-SOD1 mice.
To test potential changes in Ca2+-dependent quantal release
in ALS we applied electrical stimulation to the motor nerve.
Interestingly, unlike the dramatic drop in spontaneous release,
Ca2+-dependent evoked release during single nerve stimulation
was not changed in G93A-SOD1 mice of either sex. Thus, the
amplitudes of EPPs were 13.2 ± 3.1 mV (n = 4 mice) in the
WT, 13.4± 3.4 mV (n = 5 mice, P = 0.97 versus WT) in G93A-
SOD1 male mice (Figures 5A,B). The quantal content of action
potential-evoked transmitter release was 37.3 ± 4.7 quanta in the
WT male mice (n = 4) and 34.8± 4.3 quanta in transgenic mice
(n = 4,P = 0.71 versusWT). Likewise, in females,EPPs amplitudes
were 13.2± 1.2 mV (n = 4 mice) in the WT and 13.6± 1.7 mV
(n = 4 mice, P = 0.85 versus WT) in G93A-SOD1 mice, respec-
tively (Figures 5C,D). Thequantal content of transmitter release in
females (26.9± 1.0 quanta) did not differ signiﬁcantly from males
(n = 4, P = 0.07) and was not changed in G93A-SOD1 females
(n = 4, P = 0.53).
Taken together these data indicated that EPPs evoked by a single
action potential were unchanged. However, the fraction of vesicles
FIGURE 4 | Evaluation of the readily releasable transmitter pool in the
sucrose test. (A–C) Examples of sucrose-evoked quantal events inWT,
G93A-SOD1, and GCSF-treated G93A-SOD1 male mice, respectively. (D,E)
Histograms of mean interevent intervals inWT, G93A-SOD1, and
GCSF-treated G93A-SOD1 male (D) and female (E) mice. Note the reduced
RRP in G93A-SOD1 male mice and improvement of this parameter in
GCSF-treated animals. *=P <0.05, **=P <0.01.
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FIGURE 5 | Evoked EPPs in theWT and G93A-SOD1 mice. (A,D)
Examples of end-plate potentials (EPPs) inWT, G93A-SOD1 male, and
female mice. (B,C). Histograms showing amplitudes of evoked EPPs inWT,
G93A-SOD1 male, and female mice, respectively.
included in the RRP was reduced in G93A-SOD1 male mice and
remarkably preserved by the GCSF treatment.
PRESYNAPTIC INHIBITION BY ROS
Since oxidative stress has been implicated in ALS pathology we
next evaluated the sensitivity of motor nerve terminals to reac-
tive oxygen species (ROS). To this end we applied the diffusible
ROS, H2O2, known as a potent inhibitor of transmitter release
at the neuromuscular junction (Giniatullin and Giniatullin, 2003;
Giniatullin et al., 2006) and measured MEPPs in the period of 15–
20 min after H2O2 application. In line with previous observations,
300 μM H2O2 signiﬁcantly reduced spontaneous quantal release
of ACh in the WT males. Thus, the intervals between spontaneous
events were lengthened from 1.59± 0.07 to 3.51± 0.80 s (n = 7
mice, P = 0.02, Figures 6A,B). In G93A-SOD1 male mice, despite
the low basic level of spontaneous release, ROS application still
reduced secretion since interevent intervals were lengthened from
9.44± 1.60 to 20.17± 5.23 s (n = 4 mice, P = 0.048). The depres-
sant effect of H2O2 was also presented after GCSF treatment (not
shown).
In the WT females, interevent intervals after ROS application
were lengthened from 1.82± 0.14 to 4.41± 0.53 s (n = 8 mice,
P < 0.0001, Figure 6C) indicating sex-independent inhibitory
action of H2O2. Like in males, in G93A-SOD1 females H2O2
also increased interevent intervals (9.63 ± 1.70 s before and
17.85± 3.46 s after H2O2, n = 11 mice, P = 0.045).
Thus, after the onset of the disease G93A-SOD1 mice were
still prone to oxidative stress-induced inhibition of quantal ACh
release.
FIGURE 6 | Reactive oxygen species-induced depression of quantal
release by exogenous H2O2. (A) Examples of MEPPs in theWT mice
before (control) and after application of 300μM H2O2. (B,C) Histograms
showing the mean interevent intervals of MEPPs before (control) and after
application of 300μM H2O2 to the neuromuscular junction in male (B) and
female mice (C). Note greater depression in G93A-SOD1 males.
*=P <0.05, ***=P <0.0001.
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GCSF DIMINISHES OXIDATIVE STRESS IN G93A-SOD1 MICE
As the relative proportion of motor nerve terminals to the
total mass of the muscle is negligible, the level of oxidative
stress in motoneurons of G93A-SOD1 and WT mice was eval-
uated from the spinal cord where the cell bodies of motoneu-
rons are located. The level of endogenous peroxides in the
spinal cord, as analyzed with the FOX1 assay, was elevated in
G93A-SOD1 male mice (0.216± 0.020 μmol/mg in WT mice ver-
sus 0.301± 0.035 μmol/mg in G93A-SOD1 mice, n = 15 mice,
P = 0.046, Figure 7A). However, in G93A-SOD1 females the
level of peroxides (0.243± 0.020 μmol/mg) was undistinguish-
able from the WT (0.231± 0.026 μmol/mg, n = 9 mice, P = 0.73,
Figure 7B). Interestingly, both G93A-SOD1 males and females
responded to GCSF treatment by signiﬁcantly reduced level
of endogenous peroxides (0.181± 0.024 μmol/mg in males,
n = 9, P < 0.024, and 0.173± 0.015 μmol/mg in females, n = 9,
P < 0.013, Figures 7A,B) indicating that the therapeutic action of
this agent includes an antioxidant mechanism, but in G93A-SOD1
females endogenous compensatory mechanisms are still able to
keep the possible mutant G93A-SOD1-induced oxidative stress
within normal range at the early symptomatic stage of the disease.
DISCUSSION
Here, we have electrophysiologically characterized in G93A-SOD1
ALS mice a presynaptic decline in the neuromuscular junction,
which was more severe in male than female mice. Importantly,
we show that GCSF treatment reduced the oxidative stress in
male mice to normal range and improved their compromised
neurotransmission without having evident effect on the neu-
rotransmission in female G93A-SOD1 mice. Our results are in
agreement with the previously reported gender differences in the
incidence andprevalenceofALS (McCombeandHenderson,2010;
Alves et al., 2011) and show that the function of neuromuscular
junction can be improved in male but not female G93A-SOD1
micewithGCSF treatment. Importantly, the improvedpresynaptic
function with GCSF treatment correlated with the gender-speciﬁc
effects of GCSF on survival rate and motor performance, sug-
gesting that the function of neuromuscular junction is a site of
FIGURE 7 |The level of endogenous peroxides inWT, G93A-SOD1 mice,
and the antioxidant effect of GCSF. (A,B) Histograms showing the level
of peroxides evaluated by FOX1 assay in spinal cord preparations obtained
from male (A) or female (B)WT, G93A-SOD1, and GCSF-treated
G93A-SOD1 mice. *=P <0.05.
key pathology in ALS, reﬂecting the upcoming survival and the
efﬁcacy of neuroprotective treatment strategies in this disease.
PRIMARY PRESYNAPTIC DYSFUNCTION IN ALS
Mice expressing human G93A mutant SOD1 are the most com-
mon animal model of ALS. Even though morphological data and
the previous indirect functional approaches suggest that degener-
ation in ALS is initiated at the peripheral site (Frey et al., 2000;
Fischer et al., 2004; David et al., 2007; Carrasco et al., 2010), the
direct functional testing of the neuromuscular transmission in
terms of synaptic EPPs in G93A-SOD1 ALS mice or other ALS
animal models is not available. This is an important point since
morphological changes could occur at later uncompensated stages
of the disease, while subtle functional abnormalities could occur
much earlier. Indeed, our study reveals that many motor terminals
in the diaphragm muscle in the early disease stage were functional
but exhibited a number of dysfunctional changes. Whereas some
studies proposed that muscle ﬁbers initiate the very early changes
leading to ALS progression (Wong and Martin, 2010), our results
indicate that presynapticmachinery ismostly affected. Thus, at the
early symptomatic disease stage of 20 weeks in G93A-SOD1 mice,
the amplitude of MEPPs was unchanged. These results are consis-
tent with recent observations that expression of the mutant SOD1
in the muscle is not required for motor terminal degeneration
(Nguyen et al., 2009; Carrasco et al., 2010). Unlike in the postsy-
naptic membrane,we observed a dramatically reduced probability
of spontaneous release of ACh at the presynaptic level in both
sexes. Interestingly, in biopsies taken from the anconeus muscle of
ALS patients with uncharacterized etiology, the average frequency
of MEPPs was not changed (Maselli et al., 1993). The discrepancy
between our observation in G93A-SOD1 mice and the clinical
ﬁndings by Maselli et al. (1993) may well be due to the differ-
ence in the disease progression between the arm (anconeus) and
diaphragm muscles, etiology (a rare G93A-SOD1 mutation com-
pared to common sporadic cases), and the large interindividual
variability of the clinical study.
Alves et al. (2011) reported reduced values of amplitude and sci-
atic nerve conduction velocity and also an increased latency inALS
mice. Likewise, an increased latency of evoked EPPs was observed
in our experiments (not shown) indicating, probably, a general
trend to reduced conduction in various nerves. However, we did
not see any signiﬁcant differences in EPPs parameters of WT and
G93A-SOD1mice of either gender. Thus, it was shown in our study
that spontaneous release was compromised much more strongly
than evoked secretion underlying Ca2+-dependent EPPs. How-
ever, in the frame of oxidative mechanism of neurodegeneration in
ALS this is a very consistent observation since spontaneous release
was preferentially inhibited by the oxidative challenge (Giniatullin
et al., 2006; Tsentsevitsky et al., 2011). Moreover, unlike earlier
hypothesis, current evidence suggests the possibility of differential
regulation of spontaneous and evoked neurotransmitter release
(Ramirez and Kavalali, 2011).
In G93A-SOD1 mice of both sexes, the amplitude of EPPs
induced by a single electrical stimulation of motor nerves and
the quantal content of the evoked transmitter released was almost
as large as in the WT mice. In contrast, the sucrose test, which is
widely used for RRP measurements (Kashani et al., 2001; Moulder
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and Mennerick, 2005; Virmani et al., 2005; Vanden Berghe and
Klingauf, 2007) revealed a signiﬁcant decrease in the immediately
available transmitter pool in nerve endings of males, which was
likely one of the reasons for the dramatic drop in the spontaneous
mediator release. Reduced RRP found in males could be a reason
for the enhanced fatigability of ALS muscles at high rate ﬁring
(Schomburg et al., 2011).
EFFICIENT TREATMENT WITH GCSF IN MALES
One important result of this study with clear clinical implica-
tion is that GCSF treatment started presymptomatically at the age
of 12 weeks reduced the development of synaptic dysfunctions
in male G93A-SOD1 mice. Recently, this agent showed beneﬁ-
cial effects in animal models of ALS (Pitzer et al., 2008; Pollari
et al., 2011) and in a pilot human study (Zhang et al., 2009).
Here we show beneﬁcial effect of GCSF on the functional state of
motor terminals which appear to be the most vulnerable struc-
tures in ALS (David et al., 2007). The protective effect of GCSF
was illustrated here by increased level of spontaneous ACh release
and larger amount of synaptic vesicles in the RRP in treated male
mice. Thus,GCSF treatment prevented in males the early dysfunc-
tion of motor nerve terminals in the skeletal muscle. Remarkably,
GCSF also showed strong antioxidant effect which should con-
tribute to the complex neuroprotection in ALS. The protective
action of GCSF to save nerve terminals might involve surrounding
glial cells. In our previous study (Pollari et al., 2011) we demon-
strated that long term GCSF treatment decreases inﬂammation,
microgliosis, and astrogliosis. Astrocytes and microglia expressing
mutant SOD1 have been shown to release soluble factors that are
toxic to motoneurons (Nagai et al., 2007; Henkel et al., 2009) and
thusGCSF could exert its protection tomotor neurons by reducing
astrocyte activation. Unlike in males, in females there was no posi-
tive effect of GCSF on survival tests or ex vivo synaptic recordings.
WHY ARE FEMALE G93A-SOD1 MICE INSENSITIVE TO GCSF?
Although ALS develops also in females, the progression of this
disease is faster in males. Such puzzling sexual dimorphism is pre-
sented also in G93A-SOD1 transgenic rats (Suzuki et al., 2007) and
was conﬁrmed in our survival tests in G93A-SOD1 mice. Thus,
the treatment with GCSF was successful in males (Pollari et al.,
2011) but almost not effective in females (current study,Figure 1).
Interestingly, in our ex vivo tests at the age of 20 weeks the resting
spontaneous quantal release of ACh was similarly dropped in both
sexes. Nevertheless, also in ex vivo tests, GCSF was little effective
in females. There could be several reasons why females were resis-
tant to the therapy with GCSF. First, GCSF in a motoneuronal
cell line had better protective effect under conditions of oxidative
stress (Tanaka et al., 2006) suggesting that the prior oxidative stress
is required for GCSF-induced neuroprotection. Notably, expres-
sion of GCSF and its receptor was induced by ischemia (Schneider
et al., 2005) which is usually associated with the oxidative stress.
Thus, the gender discrepancy in the effectiveness of GCSF could
be related to higher level of oxidative stress in males. Indeed, the
increased levels of ROS were observed in male G93A-SOD1 spinal
cords but not in females suggesting that in the latter, the redox
balance between pro- and anti-oxidant mechanisms was already
shifted toward neuroprotection.
Second, in our recent study we showed that GCSF stimulated
several pathways for the neuroprotection including mobilization
of monocytes (Pollari et al., 2011). Given that GCSF has mul-
tiple targets, several mechanisms of the neuroprotection could
coexist and determine the higher effectiveness of GCSF in males.
Of course, data obtained in a mouse model cannot be directly
extrapolated to ALS patients but they elucidate cellular and mol-
ecular mechanisms of sexual dimorphism and identify a need for
new gender-speciﬁc treatments. Our study implies that the mea-
surement of a simple parameter such as the frequency of MEPPs,
could serve as a highly sensitive biomarker to test novel therapeutic
molecules in ALS.
Taken together our data provide for the ﬁrst time detailed
electrophysiological characterization of compromised synaptic
function in an animal model of ALS and demonstrate gender dif-
ferences in the decline of the presynaptic machinery at the early
symptomatic stage of the disease. The therapeutic efﬁcacy of GCSF
only in male ALS mice emphasizes the complex action of this
compound involving essential antioxidant component.
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